Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
RESEARCH TOOLSreports
Cellectar Biosciences (CLRB) Stock Price & Analysis
1,222 Followers
CLRB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.33 - $4.45
Previous Close$3.21
Volume848.74K
Average Volume (3M)1.15M
Market Cap
$103.56M
Enterprise Value$94.54M
Total Cash (Recent Filing)$9.56M
Total Debt (Recent Filing)$552.98K
Price to Earnings (P/E)-1.0
Beta1.72
Next Earnings
May 06, 2024EPS Estimate
-$0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.11
Shares Outstanding32,260,510
10 Day Avg. Volume809,088
30 Day Avg. Volume1,146,601
Standard Deviation0.20
R-Squared0.06
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-39.12
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.00
Forecast
1Y Price Target
$15.67Price Target Upside388.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Cellectar Biosciences News
Ownership Overview
14.57% Insiders
1.74% Mutual Funds
27.79% Other Institutional Investors
55.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLRB FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was $1.33 and its highest was $4.45 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Currently, no data Available
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is May 06, 2024 which is in 18 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on Mar 27, 2024. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.57 by $0.16.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -$0.49.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 32,260,510 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.57. Following the earnings report the stock price went down -5.455%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Among the largest hedge funds holding Cellectar Biosciences’s share is Consonance Capital. It holds Cellectar Biosciences’s shares valued at N/A.
---
Cellectar Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.67 (388.16% Upside)
$15.67 (388.16% Upside)
Blogger Sentiment
Bullish
CLRB Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 14.7%
Last 30 Days ▲ 14.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.16%
12-Months-Change
Fundamentals
Return on Equity
-536.81%
Trailing 12-Months
Asset Growth
-44.07%
Trailing 12-Months
Company Description
Cellectar Biosciences
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June,1996 and is headquartered in Florham Park, NJ.
---
CLRB Earnings Call
Q4 2024
0:00 / 0:00
---
CLRB Stock 12 Months Forecast
Average Price Target
$15.67
▲(388.16% Upside)
Technical Analysis
Best Analysts Covering CLRB
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+36.57%
reiterated a buy rating 23 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +36.57% per trade.
---